SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is in the spotlight as investors react to a record revenue report and raised full-year guidance, with the community actively debating whether the earnings reaction is a short-term shakeout or a sign of long-term growth. The high short interest has fueled significant discussion around the potential for a short squeeze as shareholders weigh the company's aggressive investment phase and expanding drone technology backlog against the EPS miss.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is facing significant volatility as investors debate the impact of a recent earnings miss, missed revenue targets, and concerns over future dilution to fund production timelines. While some members of the community are calling for a bearish outlook and focusing on potential liquidity issues, others view the sharp pullback as a buying opportunity, highlighting the company's substantial $1.8 billion backlog and its long-term strategic position in the space infrastructure sector.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending following the official delivery and acceptance of its Horizon 1 AI data center by Microsoft, alongside achieving NVIDIA Exemplar Cloud status. Investors are actively debating the stock's long-term derisking versus short-term price suppression, with community sentiment split between high expectations for institutional growth and frustration over persistent short interest.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors focus on the company's progress toward a Q4 2026 BLA submission for its prostate cancer therapy, alongside optimism surrounding its upcoming presentation at the August Canaccord Genuity Growth Conference. The community is actively debating the significance of recent institutional accumulation and manufacturing milestones, while weighing the potential impact of competitive oncology developments on the company's valuation.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco Systems is currently trading in the spotlight as investors digest recent double-beat quarterly results and updated long-term guidance driven by a "networking supercycle." While shares experienced significant volatility following the report, the community remains actively divided between those betting on long-term AI infrastructure growth and those concerned that the stock's recent rally left little room for immediate upside.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors digest the impact of the DaVita contract, which is being viewed as a significant operational milestone for the long-term adoption of DefenCath. While sentiment remains strongly bullish due to the contract news and recent financial updates, message boards are actively debating the company's future guidance and the ongoing influence of institutional positioning versus retail sentiment.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is trending as investors digest strong sector read-throughs from peers and a price target raise from Goldman Sachs, which highlights robust artificial intelligence server demand. The community is actively debating the company's valuation metrics and backlog health, with bulls pointing to fundamental AI infrastructure growth while some traders remain cautious about recent price volatility.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is currently a focal point for investors as the community anticipates major technical updates and potential government contract announcements following a recent earnings report. Shareholders are actively debating the company's valuation compared to sector peers and expressing strong conviction in its long-term potential, despite concerns from some over market volatility and short-term price fluctuations.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is experiencing significant market volatility as investors weigh the company's recent earnings results against aggressive long-term revenue growth guidance and the impending impact of share lockup expirations. While some community members are capitalizing on the rapid price swings, others remain skeptical about the firm's valuation, leading to an active debate between those betting on long-term institutional adoption and those expecting further downside pressure.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending as investors digest a negative opinion from European regulators regarding YARTEMLEA, while simultaneously focusing on the company's aggressive debt reduction strategy and the upcoming July 1 implementation of a permanent Medicare J-code. Community discussions remain polarized between those concerned by regulatory setbacks and those betting on long-term value through upcoming Medicare payment catalysts and potential strategic milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates PR Newswire LAUSANNE, Switzerland, Aug. 13, 2026 Second quarter 2026 net product revenue of $18.6 million...

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of +35.29% and +13.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 PR Newswire LAUSANNE, Switzerland, Aug. 6, 2026 LAUSANNE, Switzerland, Aug. 6, 2026 /PRNewswire/ -- ADC...

Alkermes (ALKS) Reports Break-Even Earnings for Q2

Alkermes (ALKS) delivered earnings and revenue surprises of +100.00% and +9.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics Announces New Employee Inducement Grant

ADC Therapeutics Announces New Employee Inducement Grant ADC Therapeutics Announces New Employee Inducement Grant PR Newswire LAUSANNE, Switzerland, July 1, 2026 LAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ --ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the...

ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA Combination Trial

ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA Combination Trial ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA Combination Trial PR Newswire LAUSANNE, Switzerland, June 30, 2026 100 r/r DLBCL patients treated at the selected 150...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT PR Newswire NEW YORK, June 25, 2026 NEW YORK, June 25, 2026 /PRNewswire...

ADC Therapeutics To Cut About 17% Of Its Staff – A Look At Some Key Details

Equity

ADC Therapeutics expects to generate annualized cost savings of about $10 million and incur one-time pre-tax charges of about $3 million.

ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA Growth Opportunities and Regulatory Priorities

ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA Growth Opportunities and Regulatory Priorities ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA Growth Opportunities and Regulatory Priorities PR Newswire LAUSANNE, Switzerland, June 24, 2026 Planned ~17...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT PR Newswire NEW YORK, June 18, 2026 NEW YORK, June 18, 2026 /PRNewswire...

$ADCT Q2 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.11 up 78.00% YoY
• Reported revenue of $19.25M up 2.17% YoY

Stocktwits

Adc Therapeutics SA

 Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.11 up 78.00% YoY
• Reported revenue of $19.25M up 2.17% YoY

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

$ADCT Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.21 up 41.67% YoY
• Reported revenue of $20.85M down -9.47% YoY
• ADC Therapeutics expects LOTIS-5 Phase 3 topline data in Q2 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end, and maintains an expected cash runway at least into 2028.

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ADCTAdc Therapeutics SA

Fundamentals

Connect Stocktwits to ChatGPT

Latest ADCT News